# BA Study of IMP4297 (20mg vs 10mg) in Healthy Male Subjects

> **NCT04351165** · PHASE1 · COMPLETED · sponsor: **Impact Therapeutics, Inc.** · enrollment: 18 (actual)

## Conditions studied

- Solid Tumor

## Interventions

- **DRUG:** IMP4297

## Key facts

- **NCT ID:** NCT04351165
- **Lead sponsor:** Impact Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-10-29
- **Primary completion:** 2021-02-11
- **Final completion:** 2021-04-30
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2021-08-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04351165

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04351165, "BA Study of IMP4297 (20mg vs 10mg) in Healthy Male Subjects". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT04351165. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*